This proposal is to study the long term health of 9,240 patients enrolled during 1969-2002 on Nationa Wilms Tumor Study (NWTS) clinical trials and to monitor their offspring for cancer and birth defects. Wit current therapy, 90% of children with Wilms tumor (WT) will be cured. Survivors, however, are at risk fo delayed complications of their disease or treatment that may compromise their quality of life. Therapy for W has changed over time but still includes surgery, multi-agent chemotherapy and (for some) radiation therapy The disease typically occurs in early childhood;thus many years of follow-up are required to appreciate it consequences for adult survivors. As the complex genetic and epigenetic events involved in the etiology an pathogenesis of WT are unraveled, we may also discover the mechanisms underlying its long-term sequela and thus help to develop appropriate preventive strategies. Our specific goals are to determine th incidence, spectrum and risk factors, including disease, treatment and host factors, for selected life threatening endpoints affecting WT survivors: a) congestive heart failure;b) respiratory failure;c) rena failure;d) second malignant neoplasms;and e) diabetes. We will determine the incidence and causes of lat mortality in WT patients and, where possible, compare mortality and chronic disease rates with nationa population rates. We will study birth rates in WT survivors, pregnancy outcomes and complications, an congenital malformations in their offspring. Heritability and recurrence risks will be estimated through study of familial disease and follow-up of offspring. We will exploit the unique NWTS resource, including.::- systematically collected information on birth weights, congenital anomalies, nephrog.enic rests, histologic type, radiation doses, therapeutic drugs and clinical outcomes, to better characterize, subgroups of patient that may differ with respect to the etiology and pathogenesis of their WT and their susceptibility to long ter complications. We will collaborate with molecular biologists by facilitating access to particularly informativ patients and by combining the laboratory, clinical, pathology and epidemiologic data for analysis. B elucidating the late complications of WT and its treatment, and by identifying susceptible subgroups, thi study will enable future generations of childhood cancer patients and their physicians to select optimu treatments based on knowledge of long term risks as well as short term benefits.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA054498-20
Application #
7996626
Study Section
Epidemiology of Cancer Study Section (EPIC)
Program Officer
Elena, Joanne W
Project Start
1991-08-15
Project End
2012-06-30
Budget Start
2010-12-01
Budget End
2012-06-30
Support Year
20
Fiscal Year
2011
Total Cost
$1,007,340
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Gratias, Eric J; Dome, Jeffrey S; Jennings, Lawrence J et al. (2016) Association of Chromosome 1q Gain With Inferior Survival in Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group. J Clin Oncol 34:3189-94
Feijen, Elizabeth A M; Leisenring, Wendy M; Stratton, Kayla L et al. (2015) Equivalence Ratio for Daunorubicin to Doxorubicin in Relation to Late Heart Failure in Survivors of Childhood Cancer. J Clin Oncol 33:3774-80
Chow, Eric J; Chen, Yan; Kremer, Leontien C et al. (2015) Individual prediction of heart failure among childhood cancer survivors. J Clin Oncol 33:394-402
Breslow, Norman E; Peterson, Susan M; Green, Daniel M (2015) Reply to Wilms tumor and breast cancer. Cancer 121:2099-100
Green, Daniel M; Breslow, Norman E; D'Angio, Giulio J et al. (2014) Outcome of patients with Stage II/favorable histology Wilms tumor with and without local tumor spill: a report from the National Wilms Tumor Study Group. Pediatr Blood Cancer 61:134-9
Maschietto, Mariana; Williams, Richard D; Chagtai, Tasnim et al. (2014) TP53 mutational status is a potential marker for risk stratification in Wilms tumour with diffuse anaplasia. PLoS One 9:e109924
Lange, Jane M; Takashima, Janice R; Peterson, Susan M et al. (2014) Breast cancer in female survivors of Wilms tumor: a report from the national Wilms tumor late effects study. Cancer 120:3722-30
Malogolowkin, M; Spreafico, F; Dome, J S et al. (2013) Incidence and outcomes of patients with late recurrence of Wilms' tumor. Pediatr Blood Cancer 60:1612-5
Peng, Gang; Fan, Yu; Palculict, Timothy B et al. (2013) Rare variant detection using family-based sequencing analysis. Proc Natl Acad Sci U S A 110:3985-90
Green, Daniel M; Lange, Jane M; Qu, Annie et al. (2013) Pulmonary disease after treatment for Wilms tumor: a report from the national wilms tumor long-term follow-up study. Pediatr Blood Cancer 60:1721-6

Showing the most recent 10 out of 51 publications